Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. provided earnings guidance for the year ended 31 December 2023. For the year, the company expects operating revenue to be between RMB 1,174.4155 million and RMB 1,201.3105 million, representing an increase of between 31% and 34% as compared with 2022. Net profit attributable to the equity owners to be between RMB 474.6484 million and RMB 492.4923 million, representing an increase of between 33% and 38% as compared with 2022.

Net profit attributable to equity owners after deducting non-recurring gains or losses to be between RMB 430.6461 million and RMB 453.3116 million, representing an increase of between 33% and 40% as compared with 2022.